Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer [Phase 3]
A Phase 3 clinical trial evaluating IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy for newly diagnosed advanced…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) [Phase 2]
This Phase 2 MATCH Screening Trial update describes ongoing evaluation of targeted therapies matched to genetic alterations in patients with…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations [Phase 2]
This clinical trial update describes a Phase 2 study evaluating talazoparib in patients with advanced cancers and DNA repair variations, and…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction [Phase 1]
Phase 1 trial evaluating veliparib, paclitaxel, and carboplatin in patients with various metastatic or unresectable solid tumors and liver o…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors [Phase 1]
Phase 1 clinical trial evaluating the combination of ZEN003694 with nivolumab, with or without ipilimumab, in metastatic and recurrent solid…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer [Phase 2]
A Phase 2 trial evaluating ONC-392 in combination with pembrolizumab for platinum-resistant ovarian cancer is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib [Phase 2]
This Clinical Trial Update reports a Phase 2 study evaluating maintenance therapy with the antibody-drug conjugate mirvetuximab soravtansine…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors [NA]
A ClinicalTrials.gov update for REVITALIZE, a randomized trial to reduce fatigue in adults with ovarian cancer on PARP inhibitors; the study…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy [Phase 2]
Phase 2 clinical trial update comparing sacituzumab govitecan with bevacizumab to standard chemotherapy for recurrent platinum-sensitive ova…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors [Phase 2]
A Phase 2 clinical trial update for trastuzumab deruxtecan (Enhertu) in HER2-expressing tumors, including bladder, biliary tract, cervical, …
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: The Registry of Genetic Alterations of Taiwan Ovarian Cancer
A Taiwan registry study collecting genetic alterations in ovarian cancer patients, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
Updates on the SENTRY study investigating platelet RNA changes to improve early diagnosis of ovarian cancer; the trial is currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence [Phase 2]
This entry describes a Phase 2 clinical trial of an IGFBP-2 vaccine to prevent ovarian cancer progression in patients with serologic evidenc…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating Ubamatamab in combination therapy for adults with platinum-resistant ovarian cancer; recruitment is ongo…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors [Phase 1]
This clinical trial update reports a Phase 1 dose-determining study of EXS74539 (REC-4539) in participants with select solid tumors, current…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians [NA]
This clinical trial aims to adapt an intervention to help ovarian cancer patients cope and to address burnout among gynecologic oncology cli…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy [Phase 3]
A Phase 3 trial comparing Rina-S plus standard of care versus standard of care for maintenance therapy in recurrent platinum-sensitive ovari…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) [Phase 3]
Phase 3 study evaluating primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer;…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer [Phase 1]
A Phase 1 clinical trial evaluating Azenosertib (ZN-c3) in patients with epithelial ovarian cancer and other solid tumors is currently recru…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors [Phase 1]
Phase I study of SYS6043 in patients with advanced or metastatic solid tumors is currently recruiting, including prostate cancer, small cell…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) [Phase 1]
Phase 1 study of ADP-A2M4CD8 as monotherapy or in combination with nivolumab or pembrolizumab in HLA-A2+ patients with MAGE-A4-positive tumo…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
A clinical trial update indicates the study on the multidimensional burden of platinum-resistant ovarian cancer on patients and caregivers i…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Intensification Treatment of Ovarian Cancer by PIPAC [Phase 2]
An ongoing Phase 2 trial from Moscow evaluating intensified treatment of advanced epithelial ovarian cancer using PIPAC (pressurized intrape…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors [Phase 1]
FT836 is being studied in a Phase 1 trial for advanced solid tumors, administered with or without chemotherapy and/or monoclonal antibodies.…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients [NA]
This clinical trial update reports on germline alterations of tumor susceptibility genes in New York cancer patients across multiple cancer …